WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: neoadjuvant_guidance_v2, Neoadjuvant therapy modifies Tissue biomarkers, All sampled ipsilateral lymph nodes has_pertinent_information Axillary lymph node (ALN) status, Progression free survival (PFS) concurrent_with Neoadjuvant therapy, No remaining palpable tumor is_measured_in Breast tissue, Neoadjuvant therapy starts_before_start_of Mastectomy, FDA Criteria for Efficacy endpoint for Breast Cancer treatment has_component Pathologic complete response (pCR), FDA Criteria for Efficacy endpoint for Breast Cancer treatment refers_to Breast Cancer, Clinical complete response (cCR) is_documented_by No remaining palpable tumor, Neoadjuvant therapy is_a Systemic therapy, Pathologic complete response (pCR) is_measured_on Resected breast tissue, Pathologic complete response (pCR) refers_to Absence of any residual invasive cancer, Pathologic complete response (pCR) provides_evidence_for Overall survival (OS), Breast Cancer has_component Early-stage breast cancer, FDA Criteria for Efficacy endpoint for Breast Cancer treatment has_component Clinical complete response (cCR), Neoadjuvant therapy has_goal Neoadjuvant therapy goals, Overall survival (OS) concurrent_with Neoadjuvant therapy, Pathologic complete response (pCR) is_measured_by Hematoxylin and eosin evaluation, No remaining palpable tumor is_measured_in ALN, Pathologic complete response (pCR) is_measured_on All sampled ipsilateral lymph nodes, Clinical complete response (cCR) concurrent_with Neoadjuvant therapy